Manns, M. P.; Wedemeyer, H.; Cornberg, M.
September 2006
Gut;Sep2006, Vol. 55 Issue 9, p1350
Academic Journal
The article presents information on current standard therapy used for the treatment of hepatitis C, its problems in special patient populations and the recent advances in the treatment of the disease to prevent chronicity. Recent advancements include the development of small molecules such as ribozymes, antisense oligonucleotides, and small interfering RNAs that have been designed to control viral gene expression.


Related Articles

  • Cell-Type Specific Interferon Stimulated Gene Staining in Liver Underlies Response to Interferon Therapy in Chronic HBV Infected Patients. Zhu, Yanling; Qin, Bo; Xiao, Chunyan; Lu, Xi; Chen, Limin // Digestive Diseases & Sciences;Sep2012, Vol. 57 Issue 9, p2355 

    Background: Interferon-α is approved as one of the main therapeutic treatments for chronic hepatitis B virus infection, but only a small number of patients achieve sustained virological response. The molecular mechanisms underlying IFN-α resistance in those patients who do not respond...

  • Possibilities for RNA Interference in Developing Hepatitis C Virus Therapeutics. Berger, Kristi L.; Randall, Glenn // Viruses (1999-4915);Aug2010, Vol. 2 Issue 8, p1647 

    The discovery and characterization of the RNA interference (RNAi) pathway has been one of the most important scientific developments of the last 12 years. RNAi is a cellular pathway wherein small RNAs control the expression of genes by either degrading homologous RNAs or preventing the...

  • A speculated ribozyme site in the herpes simplex virus type 1 latency-associated transcript gene is not essential for a wild-type reactivation phenotype. Carpenter, Dale; Singh, Sukhpreet; Osorio, Nelson; Hsiang, Chinhui; Jiang, Xianzhi; Jin, Ling; Jones, Clinton; Wechsler, Steven // Journal of NeuroVirology;Nov2008, Vol. 14 Issue 6, p558 

    During herpes simplex virus-1 (HSV-1) latency in sensory neurons, LAT (latency-associated transcript) is the only abundantly expressed viral gene. LAT plays an important role in the HSV-1 latency-reactivation cycle, because LAT deletion mutants have a significantly decreased reactivation...

  • It Didn't Work for Him. Gengler, Amanda // Money;Jun2007, Vol. 36 Issue 6, p96 

    The article discusses the use of alternative treatments by William McGill of New York State. McGill, frustrated by the side effects of the medication he had to take for his hepatitis C, began using colloidal silver. The herbal supplement helped him feel and look good, but a blood test showed the...

  • CON: The Management of Hepatitis C in a Community-Based Practice. Naffah, Farid // American Journal of Gastroenterology;Sep2007, Vol. 102 Issue 9, p1839 

    The article discusses the argument concerning the management of hepatitis C in a community based practice. According to the author, the belief that patient with chronic viral hepatitis should be managed at tertiary care institutions lies on the presumed lack of expertise outside of specialized...

  • Treatment eligibility in Alaska Native and American Indian persons with hepatitis C virus infection. Livingston, Stephen E.; Townshend-Bulson, Lisa J.; Bruden, Dana L.; McMahon, Brian J.; Homan, Chriss E.; Gove, James E.; Deubner, Heike; Bruce, Michael G.; Robinson, Renee F.; Gretch, David R. // International Journal of Circumpolar Health;2012, Vol. 71, p1 

    Objectives. Treatment with pegylated interferon and ribavirin may prevent progression of liver disease among patients with chronic hepatitis C virus infection (HCV). Treatment initiation is based on published clinical eligibility criteria, patients' willingness to undergo treatment and...

  • Neutralizing Antibodies in Patients with Chronic Hepatitis C, Genotype 1, against a Panel of Genotype 1 Culture Viruses: Lack of Correlation to Treatment Outcome Pedersen, Jannie; Jensen, Tanja B.; Carlsen, Thomas H. R.; Schønning, Kristian; Christensen, Peer Brehm; Laursen, Alex Lund; Krarup, Henrik; Bukh, Jens; Weis, Nina // PLoS ONE;May2013, Vol. 8 Issue 5, p1 

    The correlation of neutralizing antibodies to treatment outcome in patients with chronic hepatitis C virus (HCV) infection has not been established. The aim of this study was to determine whether neutralizing antibodies could be used as an outcome predictor in patients with chronic HCV, genotype...

  • Regulation of Translation Initiation under Biotic and Abiotic Stresses. Echevarría-Zomeño, Sira; Yángüez, Emilio; Fernández-Bautista, Nuria; Castro-Sanz, Ana B.; Ferrando, Alejandro; Castellano, M. Mar // International Journal of Molecular Sciences;Mar2013, Vol. 14 Issue 3, p4670 

    Plants have developed versatile strategies to deal with the great variety of challenging conditions they are exposed to. Among them, the regulation of translation is a common target to finely modulate gene expression both under biotic and abiotic stress situations. Upon environmental challenges,...

  • Calendar of Courses, Symposiums and Conferences.  // American Journal of Gastroenterology;Dec2013, Vol. 108 Issue 12, p1940 

    A calendar of courses offered by the journal for the U.S. from December 2013 till May 2014 is presented which include the ACG Southern Regional Course, the 29th Annual New Treatments in Chronic Liver Disease, and the Hepatitis C Management State of The Art.


Read the Article


Sign out of this library

Other Topics